Bremelanotide Acetate Patent Expiration

Bremelanotide Acetate is used for treating hypoactive sexual desire disorder (HSDD) in premenopausal females with controlled hypertension by injecting bremelanotide. It was first introduced by Cosette Pharmaceuticals Inc in its drug Vyleesi (Autoinjector) on Jun 21, 2019.


Bremelanotide Acetate Patents

Given below is the list of patents protecting Bremelanotide Acetate, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Vyleesi (autoinjector) US11590209 Use of bremelanotide in patients with controlled hypertension Apr 29, 2041 Cosette
Vyleesi (autoinjector) US10286034 Uses of bremelanotide in therapy for female sexual dysfunction Nov 05, 2033 Cosette
Vyleesi (autoinjector) US9352013 Uses of bremelanotide in therapy for female sexual dysfunction Nov 05, 2033 Cosette
Vyleesi (autoinjector) US9700592 Uses of bremelanotide in therapy for female sexual dysfunction Nov 05, 2033 Cosette
Vyleesi (autoinjector) US6794489 Compositions and methods for treatment of sexual dysfunction Jun 28, 2025 Cosette
Vyleesi (autoinjector) US6579968 Compositions and methods for treatment of sexual dysfunction Jun 28, 2021

(Expired)

Cosette



A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Bremelanotide Acetate's patents.

Given below is the list recent legal activities going on the following patents of Bremelanotide Acetate.

Activity Date Patent Number
Patent litigations
Payment of Maintenance Fee, 8th Yr, Small Entity 19 Nov, 2023 US9352013
Applicant Has Filed a Verified Statement of Small Entity Status in Compliance with 37 CFR 1.27 17 Nov, 2023 US9352013
Patent Issue Date Used in PTA Calculation 28 Feb, 2023 US11590209
Recordation of Patent Grant Mailed 28 Feb, 2023 US11590209
Email Notification 28 Feb, 2023 US11590209
Issue Notification Mailed 08 Feb, 2023 US11590209
Dispatch to FDC 26 Jan, 2023 US11590209
Application Is Considered Ready for Issue 26 Jan, 2023 US11590209
Issue Fee Payment Verified 24 Jan, 2023 US11590209
Issue Fee Payment Received 24 Jan, 2023 US11590209


Bremelanotide Acetate's Family Patents

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List